Drugs / Olanzapine
Olanzapine
also known as
Zyprexa · OLZ · OLA · olanzapine long-acting injection · olanzapine LAI · Arkolamyl · IM olanzapine depot · LY170053 · +35 more
Small molecule targets DRD4, HTR2A, HTR2C via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | ZYPREXA | — | 2000-03-17 – 2013-07-26 | fda.gov ↗ |
| Approved | US (FDA) | ZYPREXA | — | 1996-09-30 | fda.gov ↗ |
| Approved | EU (EMA) | Zyprexa | — | 1996-09-27 | europa.eu ↗ |
Trials 261 · started per year
today
EU approved 1996
US approved 1996
3
2
11
9
13
22
17
15
19
9
8
10
5
3
8
5
7
8
6
9
8
6
10
4
11
6
12
6
6
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03790085 | Sep 2018 → Jun 2020 | anxiety disorder, major depressive disorder, schizophrenia | Tianjin Medical University General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT02708394 | Feb 2017 → Oct 2023 | — | Wayne State University | Completed | No outcome recorded |
| Phase 120 trials | ||||||
| Phase 1 | NCT06319170 | Mar 2024 → Jan 2025 | schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06253546 | Mar 2024 → Jun 2025 | schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06107803 | Oct 2023 → Jan 2024 | schizophrenia | Minerva Neurosciences | Completed | No outcome recorded |
| Phase 1 | NCT05547100 | Sep → Nov 2022 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04987658 | Jul 2021 → Aug 2023 | bipolar I disorder | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03741478 | Oct 2019 → Jul 2026 overdue | — | Centre for Addiction and Mental Health | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03624322 | Aug → Oct 2018 | — | Impel Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03781115 | Nov 2017 → Feb 2027 expected | schizophrenia | University of Arizona | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02804568 | Jun → Aug 2016 | schizophrenia | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02087579 | Feb → Oct 2014 | bipolar disorder, depressive disorder, schizophrenia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02051387 | Jan 2013 → Aug 2017 | schizophrenia | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| Phase 1 | NCT01607762 | Feb → Apr 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00852956 | Feb → Apr 2009 | — | OBEcure Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00489593 | Oct 2006 → Dec 2013 | — | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00150215 | Jul → Oct 2005 | schizophrenia | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00648921 | Jun → Jul 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00647777 | Jun → Jul 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00647972 | May 2003 | — | Mylan Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 1 | NCT00255879 | Jan 1999 → Aug 2004 | drug-induced dyskinesia | University of California, San Diego | Completed | No outcome recorded |
| Phase 1 | NCT00094640 | — | schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT05814640 | Feb 2023 → Dec 2026 expected | major depressive disorder, splenic sequestration | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02650102 | Jan 2013 → Dec 2016 | schizophrenia | Shanxi Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00446992 | Apr 2006 → Mar 2010 | schizophrenia | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 1/2 | NCT00485810 | Jun → Nov 2004 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT01282632 | Aug 2002 → Mar 2004 | major depressive disorder | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 1/2 | NCT00089869 | — | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 234 trials | ||||||
| Phase 2 | NCT07152184 | Oct 2026 → Feb 2032 expected | schizophrenia | University Hospital, Strasbourg, France | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07581405 | Jul 2026 → Jul 2028 expected | gastric adenocarcinoma | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07455955 | Mar 2026 → Jun 2027 expected | breast cancer | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT06995508 | Dec 2025 → Nov 2030 expected | head and neck squamous cell carcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05705492 | Jul 2024 → Jun 2027 expected | biliary tract cancer, carcinoma of esophagus, colorectal carcinoma, gastric carcinoma +2 | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06554613 | Jul 2024 → Dec 2026 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06065722 | Sep → Dec 2023 | chemotherapy-induced toxicity | Simon Williamson Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT05676294 | Jun 2023 → Dec 2025 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT05179772 | Jul 2022 → Jan 2023 | substance-related disorder | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 2 | NCT05163717 | Jun 2022 → Mar 2023 | developmental delay, behavioral abnormalities, and neuropsychiatric disorders | Impel Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05170919 | Jan 2022 → Dec 2026 expected | anorexia nervosa | Englewood Hospital and Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT04750395 | Sep 2021 → May 2024 | delirium | HCA Hospice Care | Unknown | No outcome recorded |
| Phase 2 | NCT04669132 | Dec 2020 → Dec 2021 | chemotherapy-induced toxicity | Instituto Brasileiro de Controle do Cancer | Completed | No outcome recorded |
| Phase 2 | NCT05202275 | Dec 2020 → Dec 2022 | head and neck squamous cell carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04518319 | Oct 2020 → Nov 2024 | schizophrenia | Shanghai Mental Health Center | Suspended | No outcome recorded |
| Phase 2 | NCT03679182 | Sep 2018 → Sep 2020 | — | Khon Kaen University | Unknown | No outcome recorded |
| Phase 2 | NCT03575637 | Jul 2018 → May 2021 | gastric cancer | Peking University | Unknown | No outcome recorded |
| Phase 2 | NCT03478605 | May 2018 → May 2019 | chemotherapy-induced toxicity | Blokhin's Russian Cancer Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT02755116 | Apr 2016 → Sep 2019 | — | Jaime B Hyman | Completed | No outcome recorded |
| Phase 2 | NCT02462473 | May 2015 → Jan 2016 | schizoaffective disorder, schizophrenia | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT02400866 | May → Nov 2015 | cancer | Korean South West Oncology Group | Unknown | No outcome recorded |
| Phase 2 | NCT02290470 | Apr 2014 → Nov 2015 | — | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | No outcome recorded |
| Phase 2 | NCT02129478 | Mar 2014 → Jan 2016 | chemotherapy-induced toxicity | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT02097823 | Feb 2014 → Feb 2015 | chemotherapy-induced toxicity | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT01148264 | Jul 2010 → Oct 2013 | — | Karin Jordan | Terminated | No outcome recorded |
| Phase 2 | NCT00686998 | May 2008 → Mar 2009 | schizophrenia | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00678457 | Jan 2007 → May 2008 | alcohol dependence | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00316238 | Apr 2006 → May 2007 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00265551 | Jan 2006 → Jan 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00692185 | Oct 2005 → Sep 2010 | eating disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00259870 | Sep 2005 → Aug 2007 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00073164 | Jul 2003 → ? | schizophrenia | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00057408 | May 2003 → Sep 2005 | autism | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 2 | NCT00260962 | Sep 2000 → Jul 2006 | anorexia nervosa | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06175273 | Jan 2024 → Aug 2025 | childhood malignant neoplasm, muscular atrophy, nutritional deficiency disease | Corey Hawes | Completed | No outcome recorded |
| Phase 2/3 | NCT04181385 | Jan 2019 → Jan 2020 | — | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2/3 | NCT03631004 | Oct 2018 → Feb 2021 | — | Cancer Institute of the State of São Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT03137121 | Jul 2017 → Jul 2019 | cancer of unknown primary site | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2/3 | NCT00876772 | Mar 2011 → Jul 2012 | amyotrophic lateral sclerosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2/3 | NCT00183404 | Sep 2004 → Jul 2011 | autism | Drexel University | Completed | No outcome recorded |
| Phase 376 trials | ||||||
| Phase 3 | NCT07565428 | Apr 2026 → Dec 2027 expected | — | Minerva Neurosciences | Recruiting | No outcome recorded |
| Phase 3 | NCT07413809 | Oct 2025 → Sep 2027 expected | plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07035821 | Jul 2025 → Jun 2026 overdue | chemotherapy-induced toxicity, childhood malignant neoplasm | Shanghai Children's Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07633236 | Mar 2025 → Dec 2026 expected | chemotherapy-induced toxicity | Blokhin's Russian Cancer Research Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06850454 | Jan 2025 → Jan 2026 overdue | chemotherapy-induced toxicity | Mahidol University | Recruiting | No outcome recorded |
| Phase 3 | NCT06588413 | Sep 2024 → Oct 2027 expected | disease related to hematopoietic stem cell transplant, plasma cell myeloma | Augusta University | Recruiting | No outcome recorded |
| Phase 3 | NCT06500234 | Jun 2024 → May 2025 overdue | cancer, nutritional disorder | Qingdao Central Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06200181 | Apr 2024 → Nov 2026 expected | opioid abuse | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06338683 | Mar 2024 → Mar 2027 expected | — | Qinghai Red Cross Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05895838 | Jun 2023 → Sep 2027 expected | cardiac arrest, post-cardiac arrest syndrome | Christian Hassager | Recruiting | No outcome recorded |
| Phase 3 | NCT05803642 | Mar 2023 → May 2024 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05403580 | Jun 2022 → Dec 2023 | cancer, hematopoietic and lymphoid cell neoplasm | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 3 | NCT05346731 | Apr 2022 → Mar 2024 | chemotherapy-induced toxicity | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| Phase 3 | NCT05244577 | Jan 2022 → Dec 2023 | malignant testicular germ cell tumor | Shi Yanxia | Unknown | No outcome recorded |
| Phase 3 | NCT04939090 | Jan 2022 → Apr 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04987229 | Oct 2021 → Sep 2027 expected | bipolar I disorder, schizophrenia | Alkermes, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04503668 | Dec 2020 → Jan 2024 | female reproductive organ cancer | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT04536558 | Oct 2020 → Feb 2021 | chemotherapy-induced toxicity | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04535141 | Aug 2020 → Apr 2022 | chemotherapy-induced toxicity | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT04232423 | Mar 2020 → Jun 2021 | — | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| Phase 3 | NCT04437017 | Feb 2020 → May 2022 | chemotherapy-induced toxicity | Fifth Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT04075955 | Apr → Dec 2019 | chemotherapy-induced toxicity | CR-CSSS Champlain-Charles-Le Moyne | Completed | No outcome recorded |
| Phase 3 | NCT03876938 | Mar 2019 → Aug 2020 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT03510325 | Feb 2019 → Sep 2023 | schizophrenia | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 3 | NCT03578081 | Nov 2018 → Nov 2021 | cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT03367572 | Apr 2018 → Apr 2024 | breast carcinoma | University of Rochester NCORP Research Base | Completed | No outcome recorded |
| Phase 3 | NCT02939287 | Sep 2017 → Dec 2021 | — | Rush University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03219710 | Jul 2017 → Jul 2019 | chemotherapy-induced toxicity | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03201757 | Jun 2017 → Sep 2023 | bipolar I disorder, schizophrenia, schizophreniform disorder | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03079219 | Mar 2017 → Mar 2021 | breast cancer | CCTU | Completed | No outcome recorded |
| Phase 3 | NCT02873208 | Aug 2016 → Oct 2019 | schizophrenia | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02717195 | Apr 2016 → Aug 2018 | schizophrenia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02634346 | Dec 2015 → May 2017 | schizophrenia | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02484911 | May 2015 → Sep 2016 | chemotherapy-induced toxicity | First Affiliated Hospital of Harbin Medical University | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02116530 | Aug 2014 → Apr 2015 | cancer of unknown primary site, hematopoietic and lymphoid cell neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT01617200 | Dec 2012 → Mar 2015 | schizophrenia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01765829 | Nov 2012 → Nov 2015 | psychotic disorder | Fundación Pública Andaluza Progreso y Salud | Unknown | No outcome recorded |
| Phase 3 | NCT01687478 | Sep 2012 → Nov 2015 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01184443 | Aug 2010 → Aug 2013 | eating disorder | Children's Hospital of Eastern Ontario | Terminated | No outcome recorded |
| Phase 3 | NCT00970281 | Sep 2009 → Apr 2011 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00958568 | Aug 2009 → Mar 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00632645 | Apr 2009 → Apr 2017 | Huntington disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00640510 | Mar → Jul 2008 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00618748 | Feb 2008 → Sep 2010 | bipolar I disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00510146 | Aug 2007 → Mar 2010 | bipolar depression | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00440843 | Feb 2007 → Jun 2012 | schizoaffective disorder, schizophrenia | VA Connecticut Healthcare System | Withdrawn | No outcome recorded |
| Phase 3 | NCT00347425 | Dec 2006 → Feb 2008 | schizophrenia | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00401973 | Nov 2006 → Sep 2008 | schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00380224 | Jul 2006 → Sep 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00797277 | Jul 2006 → Jun 2009 | schizoaffective disorder, schizophrenia | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00350467 | Jun 2006 → Sep 2007 | schizophrenia | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00320489 | Apr 2006 → Sep 2009 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00259272 | Nov 2005 → May 2008 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00266630 | Nov 2005 → May 2009 | manic bipolar affective disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00455234 | Sep 2005 → Jul 2006 | psychotic disorder | Christian Medical College, Vellore, India | Completed | No outcome recorded |
| Phase 3 | NCT00129220 | Jul 2005 → Jan 2009 | bipolar I disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00113594 | Jun 2005 → Mar 2006 | bipolar disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00273624 | Jun 2005 → Dec 2009 | major depressive disorder | University Hospital Freiburg | Withdrawn | No outcome recorded |
| Phase 3 | NCT00124930 | May 2005 → Jun 2008 | cancer or benign tumor | Alberta Health services | Terminated | No outcome recorded |
| Phase 3 | NCT00088465 | Aug 2004 → Dec 2010 | schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00485901 | Jul 2004 → Jan 2005 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00088491 | Jun 2004 → Oct 2006 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00088478 | Jun 2004 → Apr 2005 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00091650 | Mar 2004 → Nov 2005 | borderline personality disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00088036 | Feb 2004 → Jan 2006 | borderline personality disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00485680 | Dec 2003 → Jun 2005 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00145444 | Mar 2003 → Nov 2005 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01977300 | Jan 2003 → Aug 2011 | bipolar I disorder | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00051298 | Nov 2002 → Apr 2005 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00746785 | Sep 2002 → May 2010 | alcohol dependence | The Mind Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00194064 | Jul 2002 → Feb 2006 | bipolar disorder | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00035321 | Apr 2002 → Jul 2005 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00034892 | Mar 2002 → Mar 2005 | schizophrenia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00159770 | Nov 2001 → Sep 2004 | schizoaffective disorder, schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00065273 | Jul 1998 → Jun 2001 | developmental disability | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 481 trials | ||||||
| Phase 4 | NCT07482891 | Mar → Oct 2026 expected | chemotherapy-induced toxicity | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06740890 | Jun 2025 → Apr 2027 expected | bipolar disorder, schizoaffective disorder, schizophrenia | New York State Psychiatric Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06133114 | Mar 2024 → Oct 2026 expected | — | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 4 | NCT06357104 | Feb → Mar 2024 | — | Pachankis, Yang I., M.D. | Completed | No outcome recorded |
| Phase 4 | NCT05590923 | Dec 2022 → Jul 2025 | chemotherapy-induced toxicity | The Guthrie Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT04478838 | Jun 2022 → Sep 2027 expected | schizophrenia | Centre for Addiction and Mental Health | Recruiting | No outcome recorded |
| Phase 4 | NCT03571126 | May 2019 → Oct 2022 | chemotherapy-induced toxicity, lung cancer | Zunyi Medical College | Unknown | No outcome recorded |
| Phase 4 | NCT02536846 | Nov 2017 → Nov 2019 | — | Dost Ongur | Completed | No outcome recorded |
| Phase 4 | NCT03246620 | Sep 2017 → Jun 2018 | — | The University of Hong Kong | Terminated | No outcome recorded |
| Phase 4 | NCT03066622 | Jul 2016 → May 2018 | headache disorder | HealthPartners Institute | Completed | No outcome recorded |
| Phase 4 | NCT02435654 | Aug 2015 → Dec 2018 | early-onset schizophrenia | Kunming Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02307396 | Feb 2015 → Jun 2016 | schizoaffective disorder, schizophrenia | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT02380118 | Dec 2014 → Sep 2019 | — | The University of Hong Kong | Terminated | No outcome recorded |
| Phase 4 | NCT02287259 | Nov 2014 → Mar 2019 | bipolar disorder | Tadashi Hasegawa | Completed | No outcome recorded |
| Phase 4 | NCT01893229 | Sep 2013 → Dec 2015 | bipolar disorder | Guiyun Xu | Unknown | No outcome recorded |
| Phase 4 | NCT02593734 | Jul 2013 → Jul 2015 | anxiety disorder, mood disorder, schizophrenia | University of Ghana Medical School | Completed | No outcome recorded |
| Phase 4 | NCT01920802 | Nov 2012 → Aug 2014 | — | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02137993 | Mar 2012 → May 2013 | schizoaffective disorder, schizophrenia, schizophreniform disorder | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02704962 | Jan 2012 → Feb 2016 | schizophrenia | Kaohsiung Kai-Suan Psychiatric Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01164059 | Feb 2010 → Aug 2013 | schizophrenia | University of Bremen | Completed | No outcome recorded |
| Phase 4 | NCT00982020 | Sep 2009 → May 2013 | bipolar I disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00844857 | Apr 2009 → Feb 2012 | bipolar depression | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01016145 | Apr 2009 → Jun 2010 | psychotic disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT01411930 | Mar 2009 → Mar 2010 | diabetes mellitus | Veterans Medical Research Foundation | Completed | No outcome recorded |
| Phase 4 | NCT01303601 | Jan 2009 → Oct 2010 | bipolar depression | China Medical University, China | Completed | No outcome recorded |
| Phase 4 | NCT00802100 | Dec 2008 → Sep 2009 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT01000402 | Feb 2008 → Oct 2012 | attention deficit-hyperactivity disorder, bipolar disorder | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| Phase 4 | NCT00520507 | Oct 2007 → May 2009 | bipolar disorder, depressive disorder | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT01149577 | Aug → Dec 2007 | schizophrenia | Central Institute of Psychiatry, Ranchi, India | Completed | No outcome recorded |
| Phase 4 | NCT01052389 | Jul 2007 → Jun 2012 | schizophrenia | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT00384332 | Jan 2007 → Mar 2010 | bipolar depression | Vanderbilt University | Completed | No outcome recorded |
| Phase 4 | NCT00402324 | Dec 2006 → Feb 2008 | bipolar I disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00433121 | Sep 2006 → Aug 2007 | dementia | Innlandet Hospital Trust | Completed | No outcome recorded |
| Phase 4 | NCT00324051 | May 2006 → Sep 2007 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00337662 | May 2006 → Dec 2007 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00303602 | Mar 2006 → Dec 2007 | bipolar disorder, schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00854919 | Jan 2006 → Dec 2007 | — | Osaka City University | Completed | No outcome recorded |
| Phase 4 | NCT00245206 | Aug 2005 → Oct 2010 | Alzheimer disease, schizophrenia | Veterans Medical Research Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00186017 | Jul 2005 → Jun 2010 | bipolar disorder | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00297960 | Apr 2005 → ? | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00767715 | Oct 2004 → Apr 2005 | bipolar disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 4 | NCT00094549 | Oct 2004 → Dec 2006 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00191997 | Oct 2004 → Mar 2006 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00190892 | Sep 2004 → Jun 2006 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00103571 | Jul 2004 → Aug 2006 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00090012 | Jul 2004 → Mar 2006 | schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00191399 | May 2004 → Mar 2006 | bipolar depression | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00685334 | Nov 2003 → Sep 2006 | anorexia nervosa | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT00485771 | Nov 2003 → Jan 2005 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00108368 | Oct 2003 → Mar 2006 | schizophrenia | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00190749 | Oct 2003 → Jun 2008 | schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00088049 | Oct 2003 → Jul 2007 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00182442 | Oct 2003 → Mar 2006 | schizophrenia | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00208819 | Sep 2003 → Jul 2007 | Alzheimer disease | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00100776 | Sep 2003 → Nov 2005 | schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00191555 | Aug 2003 → May 2006 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00071253 | Jul 2003 → ? | bipolar disorder | Abbott | Terminated | No outcome recorded |
| Phase 4 | NCT00485498 | Apr → Dec 2003 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00239109 | Apr 2003 → Feb 2007 | schizophrenia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00926965 | Jan 2003 → Dec 2007 | cognitive disorder, tardive dyskinesia | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00050206 | Nov 2002 → May 2005 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00048802 | Aug 2002 → Aug 2006 | bipolar disorder | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00418171 | Feb 2002 → Apr 2007 | schizophrenia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00202293 | Oct 2001 → Nov 2015 | bipolar disorder, schizoaffective disorder | Melbourne Health | Completed | No outcome recorded |
| Phase 4 | NCT00034801 | Sep 2001 → Mar 2003 | depressive disorder, schizoaffective disorder, schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00036088 | Aug 2001 → Jul 2002 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00034580 | Aug 2001 → Aug 2002 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00177567 | Jul 2001 → Jan 2004 | bipolar disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00182013 | Jun 2001 → Feb 2004 | bipolar disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00181935 | Mar 2001 → Jul 2004 | manic bipolar affective disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00014001 | Dec 2000 → Dec 2004 | schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00018668 | Oct 2000 → Sep 2004 | schizophrenia | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00621998 | Jul 2000 → Dec 2003 | tardive dyskinesia | Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00331825 | Jul 2000 → Jul 2003 | extrapyramidal and movement disease, schizophrenia | Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT00182507 | Jun 2000 → Mar 2006 | trichotillomania | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00592930 | Jun 2000 → Dec 2004 | anorexia nervosa | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00000374 | Sep 1998 → May 2007 | schizophrenia | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00007774 | Mar 1998 → Jun 2001 | schizoaffective disorder, schizophrenia | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00221481 | ? → Mar 2006 | bipolar disorder | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 4 | NCT00237861 | ? → Dec 2002 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT00236379 | ? → Aug 2003 | diabetes mellitus, schizophrenia | Janssen, LP | Completed | No outcome recorded |
| Phase not applicable36 trials | ||||||
| — | NCT07442890 | Apr 2026 → Apr 2028 expected | lung cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06251635 | Jun 2024 → Aug 2026 overdue | type 2 diabetes mellitus | Centre for Addiction and Mental Health | Recruiting | No outcome recorded |
| — | NCT05635227 | Nov 2022 → Dec 2027 expected | aortic valve disorder, coronary artery disorder | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| — | NCT06200584 | Jan → Jun 2021 | poisoning | Dr Rabia Arshad | Completed | No outcome recorded |
| — | NCT04478526 | Apr 2020 → May 2021 | generalized anxiety disorder | Dr. Nazanin Alavi | Completed | No outcome recorded |
| — | NCT04218981 | Jan 2020 → Jun 2023 | mental disorder | Central South University | Completed | No outcome recorded |
| — | NCT02970643 | Jul 2016 → Sep 2017 | chemotherapy-induced toxicity | Hee Jun Kim | Unknown | No outcome recorded |
| — | NCT02643355 | Nov 2015 → Jun 2017 | substance withdrawal syndrome | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| — | NCT01625923 | Jan 2013 → Jun 2019 | idiopathic gastroparesis | University of Michigan | Terminated | No outcome recorded |
| — | NCT04076371 | Jan 2012 → Dec 2018 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT01389908 | Jun 2011 → Jul 2014 | schizoaffective disorder, schizophrenia | Shalvata Mental Health Center | Unknown | No outcome recorded |
| — | NCT03019887 | Apr 2011 → Jan 2017 | schizophrenia | Juntendo University | Completed | No outcome recorded |
| — | NCT01170117 | Aug 2010 → Jun 2016 | anorexia nervosa | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT01539733 | Mar 2010 → Apr 2017 | cancer of unknown primary site, delirium | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT00716755 | Oct 2009 → Aug 2015 | delusional disorder, schizoaffective disorder, schizophrenia, schizophreniform disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT01057849 | Sep 2008 → Mar 2011 | schizophrenia | Peking University | Unknown | No outcome recorded |
| — | NCT00741026 | Aug 2008 → Dec 2010 | diabetes mellitus | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| — | NCT00737191 | Aug 2008 → Nov 2009 | cancer of unknown primary site, hematopoietic and lymphoid system neoplasm | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT01496183 | Oct 2007 → Apr 2013 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| — | NCT00512070 | Jul 2007 → Dec 2010 | bipolar disorder, metabolic syndrome X, obesity disorder, schizoaffective disorder +1 | Seattle Institute for Biomedical and Clinical Research | Completed | No outcome recorded |
| — | NCT00493233 | Nov 2006 → Dec 2008 | schizophrenia | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT00534183 | Jun → Dec 2006 | diabetes mellitus, metabolic syndrome X, obesity disorder | Central Institute of Psychiatry, Ranchi, India | Completed | No outcome recorded |
| — | NCT00275301 | Dec 2005 → Apr 2008 | borderline personality disorder | University of Minnesota | Completed | No outcome recorded |
| — | NCT00512291 | Jun 2005 → Aug 2007 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT01160991 | May 2004 → Oct 2006 | diabetes mellitus, schizophrenia | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| — | NCT00203307 | May 2004 → Mar 2006 | migraine disorder | Thomas Jefferson University | Terminated | No outcome recorded |
| — | NCT00222495 | Aug 2002 → Aug 2006 | schizoaffective disorder, schizophrenia, schizophreniform disorder | University of Minnesota | Completed | No outcome recorded |
| — | NCT00225498 | Jun 2002 → Oct 2008 | schizophrenia | Northwell Health | Completed | No outcome recorded |
| — | NCT01234454 | Jan 2002 → Jun 2005 | schizophrenia | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT00015548 | Mar 2001 → Oct 2004 | Alzheimer disease | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| — | NCT00205725 | Nov 2000 → Oct 2006 | schizophrenia, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00205738 | Jul 2000 → Oct 2006 | schizophrenia, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00183612 | May 2000 → Apr 2007 | bipolar disorder, psychotic disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| — | NCT00179231 | May 2000 → Feb 2004 | schizoaffective disorder, schizophrenia | Vanderbilt University | Completed | No outcome recorded |
| — | NCT01123408 | Jun 1999 → Jul 2004 | schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
| — | NCT00006195 | — | schizophrenia | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 164 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07662200 Background | Aug 2026 → Aug 2027 expected | malignant germ cell tumor | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 116 trials | ||||||
| Phase 1 | NCT06315283 Comparator | Mar 2024 → Aug 2025 | schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05964647 Comparator | Feb 2024 → Jun 2025 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT06600477 Comparator | Oct → Nov 2023 | — | Neurelis, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07190482 Comparator | Oct 2023 → Dec 2024 | tinnitus | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT05542264 Comparator | Nov 2022 → Feb 2024 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05402111 Comparator | Jun 2022 → Sep 2023 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03877562 Background | Apr 2019 → Mar 2020 | acquired hypothalamic obesity | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03565068 Background | Jun 2018 → Apr 2020 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02922426 Comparator | Sep 2016 → Jul 2017 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02634463 Background | Nov 2015 → Nov 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02181803 Background | Aug 2014 → Apr 2015 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02447835 Comparator | Aug 2012 → Dec 2014 | — | Michael Rickels | Completed | No outcome recorded |
| Phase 1 | NCT00977301 Comparator | Nov 2009 → Aug 2010 | HIV infectious disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01556763 Background | Apr → Aug 2008 | schizoaffective disorder, schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT03730857 Comparator | Jan → Dec 2008 | schizophrenia | Calo Psychiatric Center | Completed | No outcome recorded |
| Phase 1 | NCT00287352 Comparator | May 2005 → Sep 2009 | mood disorder, schizoaffective disorder, schizophrenia, schizophreniform disorder | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04718727 Comparator | Mar 2021 → Feb 2023 | — | Amani Hassan Abdel-Wahab | Completed | No outcome recorded |
| Phase 222 trials | ||||||
| Phase 2 | NCT04529226 Comparator | Nov 2020 → Jan 2025 | intellectual disability, psychotic disorder | Andalusian Public Foundation for Health Research in Seville | Unknown | No outcome recorded |
| Phase 2 | NCT03557931 Background | Jul 2018 → Oct 2019 | schizophrenia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03960151 Background | May 2018 → May 2021 | germ cell tumor | Costantine Albany | Withdrawn | No outcome recorded |
| Phase 2 | NCT03319953 Background | Dec 2017 → Sep 2019 | schizophrenia | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03118986 Comparator | Aug 2017 → Mar 2026 overdue | hematopoietic and lymphoid system neoplasm | The Hospital for Sick Children | Recruiting | No outcome recorded |
| Phase 2 | NCT02088060 Comparator | Dec 2015 → Sep 2024 | schizophrenia | Central Institute of Mental Health, Mannheim | Terminated | No outcome recorded |
| Phase 2 | NCT02161718 Comparator | May 2014 → Jan 2017 | alcohol-related disorders, schizophrenia | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01903837 Background | Jun 2013 → Dec 2014 | schizophrenia | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01323205 Background | May 2011 → Nov 2012 | schizophrenia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00988728 Comparator | Feb 2011 → Jul 2012 | schizophrenia | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT01234779 Comparator | Feb 2011 → Sep 2012 | schizophrenia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01052103 Background | Jan 2010 → Jun 2012 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00845026 Comparator | Mar 2009 → May 2010 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2 | NCT00827918 Comparator | Mar 2009 → Apr 2010 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00816894 Comparator | Jan 2009 → Feb 2013 | schizophrenia | Herzog Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00728195 Comparator | Nov 2008 → Feb 2010 | schizophrenia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00770744 Comparator | Sep 2008 → Oct 2009 | schizophrenia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT00734435 Comparator | Sep → Dec 2008 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Orexigen Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00509067 Background | Nov 2007 → Mar 2011 | schizophrenia | Georgetown University | Completed | No outcome recorded |
| Phase 2 | NCT00520923 Comparator | Sep 2007 → Oct 2008 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00483964 Comparator | Sep 2005 → Sep 2007 | schizophrenia | Q.Mundewadi Ayurvedic Research & Charitable Trust | Completed | No outcome recorded |
| Phase 2 | NCT00149292 Comparator | Aug 2005 → Jul 2006 | schizophrenia | Denovo Biopharma LLC | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT01129674 Comparator | Jun 2010 → Oct 2012 | schizophrenia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2/3 | NCT00910780 Comparator | Nov 2009 | diabetes mellitus | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 351 trials | ||||||
| Phase 3 | NCT07208305 Comparator | Feb 2026 → Dec 2027 expected | — | Affiliated Hospital of Qinghai University | Recruiting | No outcome recorded |
| Phase 3 | NCT07246187 Comparator | Nov 2025 → Oct 2026 expected | cannabinoid hyperemesis syndrome | Mercy Bon Secours Saint Vincent Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06649214 Comparator | Nov 2024 → Apr 2026 overdue | schizophrenia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06331520 Background | May 2024 → Aug 2025 | chemotherapy-induced toxicity | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT06314906 Background | Mar 2024 → Jan 2027 expected | — | Feixue Song | Recruiting | No outcome recorded |
| Phase 3 | NCT06517199 Comparator | Jan 2024 → Jan 2026 overdue | eating disorder | Mahidol University | Recruiting | No outcome recorded |
| Phase 3 | NCT06200168 Background | Jan 2024 → Oct 2026 expected | — | Jiuda Zhao | Recruiting | No outcome recorded |
| Phase 3 | NCT05669742 Comparator | May 2023 → Jun 2026 overdue | — | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT05805800 Background | Apr 2023 → Apr 2024 | chemotherapy-induced toxicity | Xingchen Peng | Completed | No outcome recorded |
| Phase 3 | NCT05303064 Comparator | Jun 2022 → Sep 2026 expected | bipolar I disorder, schizophrenia | Alkermes, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04833023 Comparator | May 2022 → Dec 2024 | delirium | Tan Tock Seng Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05242874 Background | Feb 2022 → Aug 2023 | chemotherapy-induced toxicity | Henan Cancer Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05243251 Comparator | Dec 2021 → Nov 2022 | eating disorder | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT03230864 Background | Jul 2017 → Dec 2018 | schizophrenia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 3 | NCT03187769 Comparator | Jun 2017 → Dec 2021 | bipolar I disorder, schizophrenia, schizophreniform disorder | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02861859 Comparator | Dec 2016 → Dec 2019 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT02694328 Comparator | Mar 2016 → Nov 2018 | schizophrenia | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02635984 Comparator | Nov 2015 → Dec 2017 | disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm | Augusta University | Completed | No outcome recorded |
| Phase 3 | NCT02431702 Comparator | Jul 2015 → Nov 2019 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01617187 Comparator | Dec 2012 → Aug 2014 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01081769 Comparator | Feb 2010 → Feb 2013 | schizophrenia | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT00615433 Comparator | Jan 2008 → Dec 2009 | schizophrenia | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00363376 Background | Jan 2008 → Feb 2011 | — | Lindner Center of HOPE | Completed | No outcome recorded |
| Phase 3 | NCT00568672 Comparator | Oct 2007 → Jan 2008 | — | Charite University, Berlin, Germany | Withdrawn | No outcome recorded |
| Phase 3 | NCT00645099 Comparator | Oct 2007 → Apr 2009 | schizophrenia | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT00759460 Comparator | Mar 2007 → Mar 2008 | schizophrenia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00864045 Comparator | Mar 2007 → Mar 2008 | schizophrenia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00438776 Comparator | Feb 2007 → Mar 2009 | pathological gambling | Lindner Center of HOPE | Completed | No outcome recorded |
| Phase 3 | NCT00391222 Comparator | Nov 2006 → Apr 2009 | bipolar disorder | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 3 | NCT00759421 Comparator | Oct 2006 → Mar 2008 | schizophrenia | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT00396565 Comparator | Jul 2006 → Nov 2007 | schizophrenia | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00490971 Comparator | May 2006 → Apr 2010 | bipolar disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00265343 Comparator | Dec 2005 → Dec 2007 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00211562 Comparator | Oct 2005 → Jan 2006 | schizophrenia | Augusta University | Terminated | No outcome recorded |
| Phase 3 | NCT00159783 Comparator | Jul 2005 → Apr 2007 | bipolar disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00174265 Comparator | Jul 2005 → Apr 2009 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00156117 Comparator | May 2005 → Apr 2006 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00212836 Comparator | Apr 2005 → Jun 2007 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00156091 Comparator | Apr 2005 → Jun 2007 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00151424 Comparator | Feb 2005 → Jan 2006 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00143182 Comparator | Jan 2005 → Jun 2006 | bipolar disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00149734 Background | Jan 2005 → May 2010 | schizophrenia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT00159796 Comparator | Dec 2004 → Mar 2006 | bipolar disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00145496 Comparator | Dec 2004 → Nov 2008 | schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00159744 Comparator | Nov 2004 → Apr 2006 | bipolar disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00212771 Comparator | Sep 2004 → Sep 2006 | schizoaffective disorder, schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00237913 Comparator | Jul 2004 → Aug 2005 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00177164 Comparator | Nov 2003 → Mar 2008 | bipolar I disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 3 | NCT00212784 Comparator | Sep 2003 → Mar 2006 | schizoaffective disorder, schizophrenia | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00056472 Comparator | Jan 2003 → Jun 2008 | major depressive disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 3 | NCT00712686 Comparator | Jun 2000 → Dec 2003 | schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 454 trials | ||||||
| Phase 4 | NCT07047651 Background | Jun 2025 → Dec 2027 expected | treatment-refractory schizophrenia | Dr. Stavroula Rakitzi | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05741502 Comparator | Aug 2023 → Jan 2026 | schizophrenia | Ohio State University | Terminated | No outcome recorded |
| Phase 4 | NCT03857581 Comparator | Jul 2020 → Jul 2021 | psychotic disorder, substance-related disorder | Augusta University | Unknown | No outcome recorded |
| Phase 4 | NCT04898270 Background | Dec 2019 → Dec 2020 | metabolic syndrome X, schizophrenia | Taichung Veterans General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04876521 Comparator | Oct 2019 → Jun 2021 | schizophrenia | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT03568500 Background | May 2018 → May 2019 | schizoaffective disorder, schizophrenia | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03304457 Comparator | Aug 2017 → Mar 2018 | schizophrenia | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT02562287 Comparator | Oct 2015 → Jun 2019 | bipolar disorder | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT03216941 Comparator | Jan 2015 → Jan 2016 | psychiatric disorder | Universidad Nacional de Rosario | Completed | No outcome recorded |
| Phase 4 | NCT02282085 Comparator | Dec 2014 → Dec 2017 | schizophrenia | Matt Byerly | Unknown | No outcome recorded |
| Phase 4 | NCT02237417 Comparator | Sep 2014 → Nov 2018 | schizophrenia | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT02040883 Background | Feb → Dec 2014 | schizophrenia | Qingyun Yin | Unknown | No outcome recorded |
| Phase 4 | NCT01833897 Background | Mar 2013 → Jul 2014 | bipolar disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01592201 Background | Jul 2012 → Jun 2013 | schizophrenia | Janssen Korea, Ltd., Korea | Terminated | No outcome recorded |
| Phase 4 | NCT01609153 Comparator | Jun 2012 → Apr 2019 | schizoaffective disorder, schizophrenia | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 4 | NCT01446328 Comparator | Oct 2011 → Dec 2017 | schizophrenia | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01427608 Comparator | Oct 2011 → Nov 2017 | psychotic disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT01248195 Comparator | May 2011 → Apr 2016 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Rene Kahn | Completed | No outcome recorded |
| Phase 4 | NCT01193166 Comparator | Aug 2010 → Sep 2012 | schizophrenia | Ortho-McNeil Janssen Scientific Affairs, LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT01185743 Comparator | Jul 2010 → Jan 2017 | diabetes mellitus, schizophrenia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01157351 Comparator | May 2010 → Dec 2013 | schizophrenia | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT00918021 Comparator | Jun 2009 → Jul 2010 | schizoaffective disorder, schizophrenia | Niuvanniemi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00981526 Background | Mar 2009 → May 2012 | schizoaffective disorder, schizophrenia | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 4 | NCT00806234 Comparator | Jan 2009 → Mar 2014 | psychotic disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT00895921 Comparator | Nov 2008 → Dec 2009 | diabetes mellitus | Veterans Medical Research Foundation | Completed | No outcome recorded |
| Phase 4 | NCT01864551 Comparator | Aug 2008 → Jul 2009 | bipolar disorder | Tri-Service General Hospital (TSGH) | Completed | No outcome recorded |
| Phase 4 | NCT00672464 Background | Apr 2008 → Dec 2009 | schizoaffective disorder, schizophrenia | Duke University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00508157 Comparator | Nov 2007 → Mar 2009 | metabolic syndrome X, schizophrenia | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 4 | NCT00423878 Comparator | Jan 2007 → Oct 2009 | schizoaffective disorder, schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00329108 Comparator | Nov 2006 → Jul 2007 | manic bipolar affective disorder | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00290121 Comparator | Sep 2006 → Jun 2008 | schizophrenia | University of Montreal | Completed | No outcome recorded |
| Phase 4 | NCT00338949 Comparator | Jun 2006 → Dec 2009 | metabolic syndrome X, schizophrenia | Veterans Medical Research Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00330863 Comparator | May 2006 → Jan 2011 | schizoaffective disorder, schizophrenia | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00205699 Comparator | Apr 2006 → Mar 2011 | attention deficit-hyperactivity disorder, bipolar disorder, oppositional defiant disorder, pervasive developmental disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00256997 Comparator | Jan 2006 → Apr 2009 | schizophrenia | Janssen-Ortho Inc., Canada | Terminated | No outcome recorded |
| Phase 4 | NCT00654576 Comparator | Feb 2005 → Dec 2007 | schizophrenia | Central South University | Completed | No outcome recorded |
| Phase 4 | NCT00188942 Comparator | Feb 2005 → Jun 2009 | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT00304616 Background | Oct 2004 → Jun 2006 | schizophrenia | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00246259 Comparator | Oct 2004 → Dec 2008 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Janssen-Ortho Inc., Canada | Completed | No outcome recorded |
| Phase 4 | NCT00148564 Comparator | Mar 2004 → Mar 2007 | schizophrenia | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00287820 Comparator | Feb 2004 → Sep 2007 | diabetes mellitus, hyperglycemia, metabolic syndrome X, schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
| Phase 4 | NCT00191828 Background | Mar 2003 → Aug 2005 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00932529 Comparator | Feb 2003 → Jan 2010 | psychotic disorder | University of Bergen | Completed | No outcome recorded |
| Phase 4 | NCT00486005 Background | Feb → Oct 2003 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00419653 Comparator | Jan 2003 → Sep 2007 | schizophrenia | University of Jena | Terminated | No outcome recorded |
| Phase 4 | NCT00485823 Background | Dec 2002 → Sep 2003 | schizophrenia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00053703 Comparator | Feb 2002 → May 2007 | schizophrenia | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT00048828 Comparator | Oct 2001 → Jun 2006 | schizophrenia | Northwell Health | Completed | No outcome recorded |
| Phase 4 | NCT00044655 Comparator | Jul 2001 → Mar 2009 | schizophrenia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT00183625 Comparator | Jun 2000 → Jun 2005 | schizophrenia | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT00169065 Comparator | Aug 1998 → Jun 2002 | schizophrenia | Harvard Medical School (HMS and HSDM) | Completed | No outcome recorded |
| Phase 4 | NCT00001656 Comparator | Jun 1997 → Jun 2008 | childhood-onset schizophrenia | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00000373 Comparator | Sep 1992 → Jan 2003 | obsessive-compulsive disorder | University of Florida | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT04341467 Comparator | Dec 2019 → Dec 2023 | Alzheimer disease | Tianjin Anding Hospital | Unknown | No outcome recorded |
| — | NCT03651674 Comparator | Sep 2018 → Dec 2019 | manic bipolar affective disorder, schizophrenia | Xidian University | Unknown | No outcome recorded |
| — | NCT02918825 Comparator | Sep 2016 → Aug 2017 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT02137616 Comparator | Jun 2012 → Dec 2014 | psychotic disorder | Central South University | Unknown | No outcome recorded |
| — | NCT02192723 Comparator | Jun 2012 → Jun 2014 | schizophrenia | Beijing HuiLongGuan Hospital | Completed | No outcome recorded |
| — | NCT02850445 Background | Jan 2012 → Dec 2016 | schizophrenia | Guangzhou Psychiatric Hospital | Unknown | No outcome recorded |
| — | NCT01990755 Comparator | May 2010 → May 2013 | anorexia nervosa, bulimia nervosa | University of Turin, Italy | Completed | No outcome recorded |
| — | NCT01029769 Comparator | Dec 2009 → Mar 2014 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Technical University of Munich | Completed | No outcome recorded |
| — | NCT00885690 Comparator | Apr 2009 → Nov 2012 | schizophrenia | University of Aarhus | Terminated | No outcome recorded |
| — | NCT01485692 Comparator | Feb 2009 → Mar 2011 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00910988 Comparator | Feb 2009 → Jun 2012 | hyperglycemia, hyperlipidemia | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00833300 Comparator | Jun 2008 → Nov 2011 | delirium | Richard Hall | Terminated | No outcome recorded |
| — | NCT00636896 Background | Jul 2006 → Aug 2007 | — | Neuropsychiatric Research Institute, Fargo, North Dakota | Completed | No outcome recorded |
| — | NCT00699946 Comparator | Jan 2005 → Aug 2007 | delirium | The New England Baptist Hospital | Completed | No outcome recorded |
| — | NCT00625170 Comparator | May → Dec 2004 | hyperlipidemia | Leiden University Medical Center | Completed | No outcome recorded |
| — | NCT00515723 Comparator | Sep 2001 → Dec 2008 | hyperglycemia, schizoaffective disorder, schizophrenia, type 2 diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00179062 Comparator | Feb 2000 → Jun 2007 | bipolar disorder, major depressive disorder, schizoaffective disorder, schizophrenia | Vanderbilt University | Completed | No outcome recorded |
Press releases naming this drug 19 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Teva Branded Pharmaceutical Products R&D, Inc. | The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults tevapharm.com ↗ |
| 2026-05-21 | Teva Branded Pharmaceutical Products R&D, Inc. | The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults tevapharm.com ↗ |
| 2026-02-20 | Teva Branded Pharmaceutical Products R&D, Inc. | U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults tevapharm.com ↗ |
| 2026-02-20 | Teva Branded Pharmaceutical Products R&D, Inc. | U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults tevapharm.com ↗ |
| 2025-12-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults tevapharm.com ↗ |
| 2025-12-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults tevapharm.com ↗ |
| 2025-09-21 | Teva Branded Pharmaceutical Products R&D, Inc. | New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed tevapharm.com ↗ |
| 2025-09-20 | Teva Branded Pharmaceutical Products R&D, Inc. | New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed tevapharm.com ↗ |
| 2025-09-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting tevapharm.com ↗ |
| 2025-09-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting tevapharm.com ↗ |
| 2025-05-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date tevapharm.com ↗ |
| 2025-05-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date tevapharm.com ↗ |
| 2025-03-31 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable tevapharm.com ↗ |
| 2025-03-31 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable tevapharm.com ↗ |
| 2024-11-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone) tevapharm.com ↗ |
| 2024-09-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia tevapharm.com ↗ |
| 2024-05-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia tevapharm.com ↗ |
| 2023-11-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program tevapharm.com ↗ |
| 2011-10-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Dr. Reddy's Announce Launch of Generic Zyprexa® in the United States tevapharm.com ↗ |
Evidence & citations 50 cited values
Every value below carries the sentence it was read from. 437 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olanzapine | “Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol...” NCT01323205 ↗422“Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine,...” NCT01765829 ↗ “Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of...” NCT02634463 ↗ “If the patient is within the primary medication arm and reports a 20-50% improvement in GAD symptoms compared to baseline after six weeks on the new medication, the medication...” NCT04478526 ↗ “Subjects (N = 44) who failed to respond to SSRIs were randomly assigned to 1 of 3 atypical antipsychotics -- olanzapine, quetiapine, or risperidone -- and were consecutively...” PMID 19422759 ↗ May 2009 “All the eligible participants will be randomly assigned to an oral atypical antipsychotic (risperidone, olanzapine, quetiapine, and where commercially available, aripiprazole...” NCT00256997 ↗ “Patients randomized to oral comparator arm will receive oral antipsychotics (haloperidol, paliperidone ER, risperidone, olanzapine, quetiapine or aripiprazole) as per...” NCT01081769 ↗ “For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone,...” NCT02181803 ↗ “Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3...” PMID 32141723 ↗ Mar 2020 “Concomitant therapy with antipsychotic medication (aripiprazole \[10 to 30 mg/day\], olanzapine \[10 to 20 mg/day\], paliperidone \[3 to 12 mg/day\], or risperidone \[2 to 16 mg/day\])” NCT01556763 ↗ “Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.” NCT00246259 ↗ “Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg” NCT06200168 ↗ “INP105 is a drug-device combination of olanzapine and technology that delivers a powder formulation of olanzapine to the vascular-rich upper nasal space.” PMID 32609960 ↗ Jun 2020 “United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)” NCT01052103 ↗ “comparison of intramuscular olanzapine and ketamine efficacy as first medication for fast sedation of patients with agitation and aggressive behavior.” NCT03216941 ↗ “Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.” NCT03319953 ↗ “Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics” NCT05741502 ↗ “An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.” NCT00149734 ↗ “Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder” NCT00177164 ↗ “Patients received blindly olanzapine (5-20 mg/day; N=105), haloperidol (2.5-10 mg/day; N=20), or placebo (N=99) for 3 weeks.” PMID 22134043 ↗ Nov 2011 “Olanzapine will be gradually increased to a target dose of 10mg/samidorphan 5mg (Range: 5-20mg Olanzapine/samidorphan 5mg)” NCT04987658 ↗ “Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.” NCT00338949 ↗ “Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.” NCT00520923 ↗ “INP105 is a novel combination product that sprays a powder formulation of olanzapine to the upper nasal space.” NCT05163717 ↗ “5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder” NCT05547100 ↗ “Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg” NCT01016145 ↗ “and olanzapine, an antipsychotic which blocks multiple neurotransmitters in the central nervous system.” NCT06065722 ↗ “Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group” NCT04218981 ↗ “Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression.” NCT01833897 ↗ “Multi-acting receptor-targeted antipsychotics (MARTAs): clozapine, olanzapine, quetiapine.” NCT04898270 ↗ “Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)” NCT00852956 ↗ “Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4” NCT06314906 ↗ “Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan” NCT02873208 ↗ “AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone” NCT03565068 ↗ “intramuscular olanzapine or intramuscular haloperidol plus promethazine” PMID 17954514 ↗ Oct 2007 “Olanzapine and Samidorphan fixed dose coated tablet taken once daily” NCT04987229 ↗ “Olanzapine(according to response, and tolerance)2.5-20mg” NCT01000402 ↗ “ALKS 3831 is composed of a flexible dose of olanzapine” PMID 30348514 ↗ Oct 2018 “olanzapine,clozapine,magnesium valproat,etc.” NCT03651674 ↗ “Olanzapine + samidorphan, daily oral dosing” NCT03201757 ↗ “- Olanzapine 2'5-20 mg/d. N05AH03” NCT01305707 ↗ “olanzapine (Zyprexa®)” NCT02237417 ↗ “Olanzapine” NCT05244577 ↗ |
| Known as | Arkolamyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | IM olanzapine depot | “Olanzapine Pamoate (OP) Depot (formerly referred to as IM olanzapine depot in previous versions of protocol) consists of OPM powder, which is suspended in an aqueous vehicle...” NCT01389908 ↗ |
| Known as | LY170053 | “The depot formulation of olanzapine (LY170053) to be evaluated in this study is olanzapine pamoate monohydrate (OPM) (the salt of pamoic acid and olanzapine), suitable for deep...” NCT01389908 ↗ |
| Known as | NRL-4 | “NRL-4, a nasal spray formulation of the atypical antipsychotic olanzapine is being developed by Neurelis Inc.” NCT06600477 ↗ |
| Known as | OLA | “the AP olanzapine (OLA) inhibits the ability of a central insulin stimulus (acting at the level of the brain) to decrease endogenous glucose production (EGP)” NCT03741478 ↗2“This study examines the efficacy of low-dose combined olanzapine (OLA) and sertraline on depressive and negative symptoms in patients with TRS.” PMID 37153770 ↗ Apr 2023 “the dopamine (DA) 2 antagonist olanzapine (OLA) or placebo (PLA)” NCT00000373 ↗ |
| Known as | OLAI | “olanzapine long-acting injection (OLAI) by means of a categorical approach” PMID 22935168 ↗ Aug 2012 |
| Known as | Olansek | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapin | “olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients)” NCT05895838 ↗ |
| Known as | Olanzapina | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine (as embonate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine (Zyprexa) | “Olanzapine (Zyprexa)” NCT00512070 ↗ |
| Known as | Olanzapine apotex | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine cipla | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine cipla (previously olanzapine neopharma) | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine component of lybalvi | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine component of symbyax | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine embonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine glenmark | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine glenmark europe | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00485680 ↗ |
| Known as | olanzapine LAI | “Early response/non-response to olanzapine LAI predicted later response/non-response with high sensitivity (85%), specificity (72%), PPV (78%), NPV (80%), and overall accuracy (79%).” PMID 21943257 ↗ Sep 20111“olanzapine LAI was also compared with” PMID 24041270 ↗ Sep 2013 |
| Known as | olanzapine long-acting injection | “a new injectable formulation of olanzapine, olanzapine long-acting injection (LAI), relative to placebo for treatment of acutely ill patients with schizophrenia.” PMID 18452346 ↗ May 20082“Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid.” PMID 20537130 ↗ Jun 2010 “olanzapine long-acting injection (LAI)” PMID 21823172 ↗ Aug 2011 |
| Known as | Olanzapine mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olanzapine Pamoate | “Olanzapine Pamoate (OP) Depot (formerly referred to as IM olanzapine depot in previous versions of protocol) consists of OPM powder, which is suspended in an aqueous vehicle...” NCT01389908 ↗ |
| Known as | Olanzapine pamoate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | olanzapine pamoate monohydrate | “The depot formulation of olanzapine (LY170053) to be evaluated in this study is olanzapine pamoate monohydrate (OPM) (the salt of pamoic acid and olanzapine), suitable for deep...” NCT01389908 ↗ |
| Known as | Olanzapine Stada | “The olanzapine kit will consist of two capsules each containing two 2.5 mg tablets of olanzapine (Olanzapine Stada®, STADA Nordic); i.e. total dose 10mg.” NCT05635227 ↗ |
| Known as | Olanzapine Tablets | “Olanzapine Tablets” NCT05244577 ↗ |
| Known as | Olanzapine teva | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olazax | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Olazax disperzi | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | OLZ | “Study period 1 responders (mean modal daily OFC dosage, 10.8/27.8 mg) were randomized to OFC continuation treatment or olanzapine (OLZ) monotherapy starting at 10 mg (12 weeks, SP2).” PMID 19593175 ↗ Aug 20093“Chronically ill patients treated with olanzapine (OLZ) experienced significantly greater improvement in productivity” PMID 21586165 ↗ May 2011 “2. 320 begin double-blind treatment with olanzapine (OLZ)” NCT00014001 ↗ “Olanzapine (OLZ) is an atypical antipsychotic agent” NCT05243251 ↗ |
| Known as | OP Depot | “Olanzapine Pamoate (OP) Depot (formerly referred to as IM olanzapine depot in previous versions of protocol) consists of OPM powder, which is suspended in an aqueous vehicle...” NCT01389908 ↗ |
| Known as | OPM | “Olanzapine Pamoate (OP) Depot (formerly referred to as IM olanzapine depot in previous versions of protocol) consists of OPM powder, which is suspended in an aqueous vehicle...” NCT01389908 ↗ |
| Known as | QLG2072 | “generic olanzapine injection (QLG2072) in managing acute agitation associated with schizophrenia/bipolar I disorder in Chinese patients” PMID 41778148 ↗ Feb 2026 |
| Known as | Zalasta | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | ZYP | “This study will evaluate the efficacy of divaproex sodium (DVPX) vs. olanzapine (ZYP) vs. for alcohol relapse prevention and secondary mood stabilization.” NCT00221481 ↗ |
| Known as | Zypadhera | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Zyprexa | “The goals of this study are to:
Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different points in time after an injection, and compare these...” NCT00094640 ↗20“A Multicenter, Randomized, Double-Blind, Parallel Group Study, Comparing The Efficacy And Tolerability Of Ziprasidone (Zeldox, Geodon) vs. Olanzapine (Zyprexa) In The Treatment...” NCT00329108 ↗ “This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia.” NCT00380224 ↗ “A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer” NCT00124930 ↗ “This study will compare clozapine and olanzapine (Zyprexa®) for the treatment of children and adolescents who have failed standard antipsychotic treatment for schizophrenia.” NCT00048828 ↗ “This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.” NCT00000374 ↗ “whether Quetiapine (Seroquel) is significantly more effective than Olanzapine (Zyprexa) in improving neurocognitive deficits, community functioning and quality of life” NCT00182442 ↗ “This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children.” NCT00183404 ↗ “Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify)” NCT00177164 ↗ “olanzapine (Zyprexa), risperidone (Risperdal) or quetiapine (Seroquel)” NCT00048802 ↗ “OLA group: olanzapine (Zyprexa)10 mg oral each night on days 1-4.” NCT05590923 ↗ “Risperdal (risperidone) versus Zyprexa (olanzapine)” NCT00179062 ↗ “The trade name for this drug is Zyprexa®.” NCT00203307 ↗ “Zyprexa® Tablets 5 mg” NCT00647777 ↗ “olanzapine (Zyprexa®)” NCT02237417 ↗ “olanzapine (Zyprexa)” NCT00057408 ↗ “Olanzapine (Zyprexa)” NCT00440843 ↗ “olanzapine (Zyprexa)” NCT00181935 ↗ “olanzapine/Zyprexa” NCT00910988 ↗ |
| Known as | Zyprexa IntraMuscular | “The goals of this study are to: Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different points in time after an injection, and compare these...” NCT00094640 ↗ |
| Known as | Zyprexa relprevv | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Zyprexa velotab | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Known as | Zyprexa zydis | ChEMBL registry synonym — accepted as the source's own label CHEMBL715 ↗ |
| Action | Inhibit | “the dopamine (DA) 2 antagonist olanzapine (OLA)” NCT00000373 ↗2“Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL715 ↗ “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL715 ↗ |
| Modality | Small molecule | “The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)\[1,5\]benzodiazepine.” NCT02447835 ↗ |
| Route | Oral | “5 to 20 mg/d of oral olanzapine” PMID 17851042 ↗ Sep 2007 |
| Target | DRD4 | “We decided to test olanzapine because it also targets the D4 receptor, although not as strongly as clozapine” NCT00746785 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL715 ↗ |
| Target | HTR2C | “Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL715 ↗ |